October 3rd 2023
The degree of toxicity following pediatric ingestion of THC was correlated to the dose of THC, as ingestions of 1.7 mg/kg or more was predictive of severe and prolonged toxicity, according to a study published in Pediatrics.
An increased risk of cerebral palsy was observed in children conceived in the winter and spring compared to summer, according to a recent study published in JAMA Network Open.
Fitness benefits of additional after-school physical activity were observed for school children in China compared to choice of activity, while academic performance was not compromised according to a recently published study in JAMA Pediatrics.
Results from the phase 3 MIRA-4 pediatric trial demonstrated a favorable safety and tolerability profile with no reported adverse events. Rupa Wong, MD, offers thoughts on the approval, and why it may not change day-to-day practice when it comes to the pediatric population.
In collaboration with Contemporary Pediatrics, Contemporary OB/GYN, and Contagion, Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the benefits of having new tools to fight RSV in infants, potential vaccine hesitancy, and RSV trends currently being observed.
Peter C. Jenkins, MD, MSc, details his study recently published in Jama Network Open, evaluating associations between pediatric emergency department readiness and mortality, and if children of all races benefited equitably.
Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on the latest issue of Contemporary Pediatrics, including her concern with using ChatGPT for medical information and decisions.
Ahead of the first fall and winter virus seasons in which vaccines are available for COVID-19, influenza, and respiratory syncytial virus (RSV), the Centers for Disease Control and Prevention is recommending Pfizer’s maternal vaccine to protect newborns from severe RSV illness.
Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.
Based on recent positive phase 3 results, Arcutis Biotherapeutics,. intends to submit a supplemental New Drug Application with the FDA for roflumilast cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years.
The FDA issued the Complete Response Letter (CRL) based on the request for a completed pharmacokinetic/pharmacodynamic study to assess how repeat doses of the epinephrine nasal spray compare to repeat doses of an epinephrine injection product. ARS Pharma is set to file a Formal Dispute Resolution Request to appeal the CRL.
Francheska M. Merced-Nieves, PhD, Assistant professor, Departments of Pediatrics and the Institute for Exposomic Research of Environmental Medicine & Public Health, Icahn School of Medicine at Mount Sinai, explains the associations prenatal exposure to a metal mixture and the potential negative effects for the infant.
According to a recent C.S. Mott Children’s Hospital National Poll on Children’s Health, the recent wildfires and extreme weather events that are creating poor or unhealthy air quality are also causing concern for parents in regards to their children's health.
Standout updates include a relaxed recommendation for patients with a history of egg allergies, and that all available influenza vaccines for the 2023 to 2023 flu season are quadrivalent.